Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment

Core Insights - Alkermes is a global biopharmaceutical company focused on therapies for psychiatric and neurological conditions, with a stable revenue stream from its core portfolio [1] Group 1: Company Overview - Alkermes has shifted its focus towards neuroscience, enhancing its core portfolio which includes products like Lybalvi for schizophrenia [1] Group 2: Financial Performance - The company’s main commercial products are generating stable revenues, indicating a solid market position [1]